Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration.
暂无分享,去创建一个
Frazier | R. Huddart | T. Powles | D. Feldman | C. Rodríguez-Galindo | A. L. Frazier | P. Grimison | C. Sweeney | D. Gershenson | J. Amatruda | A. Covens | M. Krailo | S. Stoneham | M. Murray | C. Thornton | J. Nicholson | D. Stark | J. Hale | H. Dang | T. Olson | G. Arul | D. Billmire | J. Hurteau | S. Stenning | F. Pashankar | Sahar A. Khaleel | G. Chinnaswamy | L. Fernando | L. F. Lopes | S. Abouelnaga | Dos Santos | Furqan Shaikh | Simone dos Santos Agular | Deborah F. Billmore | Simone Lopes | Girish Agular | Sahar Chinnaswamy | Khaleel Sherif | Juliet P Abouelnaga | Hale A. Lindsay | M. Murray
[1] M. Bains,et al. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Jaime Prat,et al. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication , 2015, Journal of gynecologic oncology.
[3] C. Rodríguez-Galindo,et al. Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Wit. Optimal Management of Clinical Stage I Nonseminoma: New Data for Patients to Consider , 2014 .
[5] N. Coleman,et al. Biology of childhood germ cell tumours, focussing on the significance of microRNAs , 2014, Andrology.
[6] J. Whelan,et al. Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials. , 2014, The Lancet. Oncology.
[7] V. Margulis,et al. A comparison of pediatric, adolescent, and adult testicular germ cell malignancy , 2014, Pediatric blood & cancer.
[8] C. Rodríguez-Galindo,et al. Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children's Oncology Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Jaime Prat,et al. Staging classification for cancer of the ovary, fallopian tube, and peritoneum , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[10] A. L. Frazier,et al. Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: A report of the children's oncology group (COG) , 2013, Pediatric blood & cancer.
[11] T. Powles,et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Culine,et al. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Bains,et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Healey,et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Rodríguez-Galindo,et al. Carboplatin (CBP) versus cisplatin (CP) within prognostic groups in pediatric extracranial malignant germ cell tumors (MGCTs). , 2012 .
[16] N. Coleman,et al. Testicular cancer: A new generation of biomarkers for malignant germ cell tumours , 2012, Nature Reviews Urology.
[17] L. Collette,et al. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] T. Powles,et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Huddart,et al. A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604) , 2011, European urology.
[20] L. Collette,et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] J. Ross,et al. Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006 , 2010, Cancer.
[22] M. Stockler,et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. , 2010, Journal of the National Cancer Institute.
[23] M. Bains,et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Li-Xuan Qin,et al. Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] P. A. Lopes,et al. Cisplatin and etoposide in childhood germ cell tumor: brazilian pediatric oncology society protocol GCT-91. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] I. Lewis,et al. Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: Report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group , 2008, British Journal of Cancer.
[27] S. Tavaré,et al. Pediatric malignant germ cell tumors show characteristic transcriptome profiles. , 2008, Cancer research.
[28] W. London,et al. Application of the adult International Germ Cell Classification System to pediatric malignant non‐seminomatous germ cell tumors: A report from the Children's Oncology Group , 2008, Pediatric blood & cancer.
[29] R. Motzer,et al. Medical treatment of advanced testicular cancer. , 2008, JAMA.
[30] S. Perkins,et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. , 2007, The New England journal of medicine.
[31] R. Motzer,et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A. Bleyer. ADOLESCENT AND YOUNG ADULT (AYA) ONCOLOGY: The First A , 2007, Pediatric hematology and oncology.
[33] M. Bains,et al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] L Collette,et al. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948) , 2005, British Journal of Cancer.
[35] J. Bacik,et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] W. London,et al. Amifostine does not protect against the ototoxicity of high‐dose cisplatin combined with etoposide and bleomycin in pediatric germ‐cell tumors , 2005, Cancer.
[37] I. Tannock,et al. Repopulation of cancer cells during therapy: an important cause of treatment failure , 2005, Nature Reviews Cancer.
[38] W. London,et al. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] J. Richie. Excellent Outcome in Patients With Stage I Germ Cell Tumors of the Testes: A Study of the Children’s Cancer Group/Pediatric Oncology Group , 2004 .
[40] W. London,et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Paul J Catalano,et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors , 2003, Cancer.
[42] M. Fritsch,et al. Genetic analysis of mediastinal nonseminomatous germ cell tumors in children and adolescents , 2002, Genes, chromosomes & cancer.
[43] Richard Sposto,et al. Cure model analysis in cancer: an application to data from the Children's Cancer Group , 2002, Statistics in medicine.
[44] R. Motzer,et al. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] H. Jürgens,et al. Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] J. Mann,et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] D. Harms,et al. Germ-cell tumors in childhood and adolescence , 2000 .
[48] D. Harms,et al. Primary mediastinal germ cell tumors in children and adolescents: results of the German cooperative protocols MAKEI 83/86, 89, and 96. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] C. Patte,et al. Non-seminomatous ovarian germ cell tumours in children. , 2000, European journal of cancer.
[50] C. Patte,et al. Prognostic factors in children with localized malignant nonseminomatous germ cell tumors. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] L. Einhorn,et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] R Sylvester,et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] R H Begent,et al. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[54] S. Fosså,et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] P. Wilkinson,et al. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] C. Bokemeyer,et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[57] M. Krailo,et al. Results of treatment of malignant germ cell tumors in 93 children: a report from the Childrens Cancer Study Group. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] J. Mann,et al. Results of the United Kingdom children's cancer study group's malignant germ cell tumor studies , 1990, Cancer.
[59] C. Stringer,et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] W. M. Linehan,et al. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] L. Einhorn,et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.
[62] S. Vogl,et al. Is there cumulative or delayed toxicity from Cis‐platinum? , 1983, Cancer.
[63] D. Cooney,et al. The use of different induction and maintenance chemotherapy regimens for the treatment of advanced yolk sac tumors. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] L. Einhorn,et al. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. , 1977, Annals of internal medicine.
[65] M. Stockler,et al. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). , 2014, Annals of Oncology.
[66] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[67] D. Harms,et al. Germ-cell tumors in childhood and adolescence. GPOH MAKEI and the MAHO study groups. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] L. Ries,et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. , 1999 .
[69] C. R. Pinkerton,et al. Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.